FDA Panel on Drug-Eluting Stents - Day 2

Yesterday, in its second of 2 days of deliberation, the FDA's Circulatory Systems Devices Advisory Panel on drug-eluting stents (DES) considered what recommendations to make regarding the off-label usage of DES.

In general, the panel agreed that the risk of late thrombosis with DES is higher when these stents are used for off-label indications than when used for on-label indications, and that, at least for patients at highest risk for stent thrombosis, the off-label use of DES should be curtailed to at least some degree.

Click here for more details on the FDA panel's deliberations.